- Home
- / Theriva Biologics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Theriva Biologics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.5
2024-10-29
Market Capitalization
$3.3 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General and administrative expense | 2.6M | 5.0M | 5.8M | 6.0M | 8.1M | 10.1M | 7.5M | 5.7M | 4.6M | 5.0M | 6.5M | 9.9M | 7.1M | 7.4M | 15.4M |
| Operating expense total | 5.9M | 17.3M | 12.3M | 20.5M | 41.0M | 39.3M | 26.3M | 17.6M | 15.7M | 10.2M | 21.6M | 19.4M | 24.1M | ||
| EBIT | (7.6M) | (17.3M) | (12.3M) | (20.5M) | (41.0M) | (39.3M) | (26.3M) | (17.6M) | (15.7M) | (10.2M) | (14.3M) | (21.6M) | (21.4M) | (26.3M) | (24.1M) |
| Interest income | 14.0K | 33.0K | 33.0K | 3.0K | 6.0K | 37.0K | 21.0K | 67.0K | 283.0K | 44.0K | 6.0K | 512.0K | 1.4M | 697.0K | 287.0K |
| Interest expense | 10.8M | 4.2M | 283.0K | ||||||||||||
| Pre tax profit | (5.9M) | (17.3M) | (12.3M) | (21.1M) | (20.0M) | (25.7M) | (23.7M) | ||||||||
| Income tax expense | (1.4M) | (1.6M) | |||||||||||||
| Net Income | (8.1M) | (17.1M) | (12.3M) | (19.8M) | (43.7M) | (27.3M) | (15.2M) | (13.4M) | (15.3M) | (10.1M) | (14.3M) | (19.7M) | (18.3M) | (25.7M) | (23.7M) |
| EPS | (1.3) | (1.0) | (19.0) | (2.1) |